EyePoint outlines mid-2026 topline data target for DURAVYU in wet AMD and DME as Phase III trials advance
Source: SeekingAlpha
2026-03-04 17:12:48 ET
More on EyePoint Pharmaceuticals
- EyePoint, Inc. (EYPT) Q4 2025 Earnings Call Transcript
- EyePoint, Inc. (EYPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Seeking Alpha’s Quant Rating on EyePoint Pharmaceuticals
- Historical earnings data for EyePoint Pharmaceuticals
- Financial information for EyePoint Pharmaceuticals
Read the full article on Seeking Alpha
For further details see:
EyePoint outlines mid-2026 topline data target for DURAVYU in wet AMD and DME as Phase III trials advance
EyePoint Pharmaceuticals Inc.
NASDAQ: EYPT
EYPT Trading
-6.13% G/L:
$15.095 Last:
659,988 Volume:
$15.27 Open:
EYPT Latest News
EYPT Stock Data
$1,131,701,297
61,949,677
0.67%
44
N/A
Biotechnology & Life Sciences
Healthcare
US
Watertown
